Amalgamated Bank Provention Bio, Inc. Transaction History

Amalgamated Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	SELL	$6.7 - $24.21 $5,561 - $20,094	-830 Reduced 8.79%	8,611 $208,000
Q4 2022 Feb 10, 2023	BUY	$4.52 - $10.57 $2,024 - $4,735	448 Added 4.98%	9,441 $100,000
Q3 2022 Nov 09, 2022	BUY	$3.43 - $5.62 $1,444 - $2,366	421 Added 4.91%	8,993 $40,000
Q2 2022 Aug 15, 2022	BUY	$3.65 - $7.3 $6,810 - $13,621	1,866 Added 27.83%	8,572 $34,000
Q1 2022 Jun 30, 2022	BUY	$3.4 - $7.88 $22,800 - $52,843	6,706 New	6,706 $49,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.